Coherus BioSciences Inc (CHRS)

20.15
NASDAQ : Health Care
Prev Close 20.15
Day Low/High 0.00 / 0.00
52 Wk Low/High 14.00 / 31.98
Avg Volume 526.50K
Exchange NASDAQ
Shares Outstanding 51.29M
Market Cap 1.03B
EPS -3.00
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Oversold Conditions For Coherus BioSciences (CHRS)

Oversold Conditions For Coherus BioSciences (CHRS)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Here's What Blackstone Bought and Sold in the Fourth Quarter

Here's What Blackstone Bought and Sold in the Fourth Quarter

Private equity firms' publicly traded equity holdings are a valuable source of ideas for growth and value investors, alike.

Here's What Blackstone and KKR Are Buying

Here's What Blackstone and KKR Are Buying

Private equity firms' publicly traded equity holdings are a valuable source of ideas for growth and value investors, alike.

Coherus BioSciences Reports Third Quarter 2016 Operating And Financial Results

Coherus BioSciences Reports Third Quarter 2016 Operating And Financial Results

Continued execution on multiple fronts positions the company strongly for the remainder of 2016 and beyond

Notable Monday Option Activity: CHRS, FMI, OLED

Notable Monday Option Activity: CHRS, FMI, OLED

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Coherus BioSciences Inc , where a total of 1,527 contracts have traded so far, representing approximately 152,700 underlying shares. That amounts to about 43.6% of CHRS's average daily trading volume over the past month of 350,515 shares.

AbbVie Notches Legal Win Over Coherus

But AbbVie still contends it should retain exclusivity on its lucrative Humira into the next decade.

AbbVie Stock Higher on Humira Patent Win

AbbVie Stock Higher on Humira Patent Win

The Patent Trial and Appeal Board has denied Coherus's petition to make a copy of AbbVie's Humira drug.